

NIH SenNet Consortium to map senescent cells throughout the human lifespan to understand physiological health

Received: 24 May 2022

SenNet Consortium*

Accepted: 28 October 2022

Published online: 20 December 2022

 Check for updates

Cells respond to many stressors by senescing, acquiring stable growth arrest, morphologic and metabolic changes, and a proinflammatory senescence-associated secretory phenotype. The heterogeneity of senescent cells (SnCs) and senescence-associated secretory phenotype are vast, yet ill characterized. SnCs have diverse roles in health and disease and are therapeutically targetable, making characterization of SnCs and their detection a priority. The Cellular Senescence Network (SenNet), a National Institutes of Health Common Fund initiative, was established to address this need. The goal of SenNet is to map SnCs across the human lifespan to advance diagnostic and therapeutic approaches to improve human health. State-of-the-art methods will be applied to identify, define and map SnCs in 18 human tissues. A common coordinate framework will integrate data to create four-dimensional SnC atlases. Other key SenNet deliverables include innovative tools and technologies to detect SnCs, new SnC biomarkers and extensive public multi-omics datasets. This Perspective lays out the impetus, goals, approaches and products of SenNet.

Senescence is a cell state triggered by numerous cell-intrinsic and cell-extrinsic stressors, including mitotic, oxidative, genotoxic, mechanical or nutrient stress, and organelle dysfunction¹. Senescence is driven by p53–p21^{CIP1} and p16^{INK4a}–Rb tumor suppressor pathways and possibly other signaling mechanisms^{1–3}. The senescence response is amplified by several mediators, including ATM, IKK–NF-κB, JAK–STAT, GATA-4 and mTOR. SnCs generally increase in size and protein content, show altered organelle function, chronic genotoxic stress, a robust secretome and resistance to apoptosis¹. One common characteristic of SnCs is a stable cell cycle arrest, which prevents a damaged cell from replicating, acquiring mutations and instigating tumorigenesis.

Multiple lines of evidence suggest that SnCs drive aging and diverse age-related diseases in preclinical models^{1,4–10}. Interventions targeting SnCs impact multiple morbidities of old age¹¹. The senescence-associated secretory phenotype (SASP) includes proinflammatory cytokines, chemokines, growth factors, proteases, receptors, extracellular vesicles, bioactive lipids and extracellular

matrix proteases^{12–14}. The SASP can drive loss of tissue homeostasis and secondary senescence, but also attract immune cells that mediate tissue regeneration and clear SnCs¹⁵. SnCs also have important roles in normal physiology, for example, embryonic development, parturition and wound healing^{16,17}. The tools to discriminate between pathological and physiological SnCs are currently lacking.

In 2011, it was established that genetic clearance of SnCs delays the onset of multiple age-related pathologies in transgenic mice¹⁸. In 2016, it was established that genetic clearance of SnCs in mice delays all-cause mortality, extending median not maximum lifespan¹⁹, implicating SnCs in many diseases that kill mice, including cancer, chronic kidney disease and cardiomyopathy¹⁹. These genetic studies incentivized the development of senotherapeutics—drugs that selectively target SnCs, either killing them (senolytics) or suppressing the SASP (senomorphics). The first senolytics were described in 2015 (ref. ²⁰). Since then, dozens of senotherapeutics have been described, including natural products^{21,22}, repurposed drugs^{6,23}, peptides²⁴, proteolysis-targeted chimeras²⁵ and chimeric antigen receptor T cells²⁶.

*A list of authors and their affiliations appears at the end of the paper. ✉ e-mail: patty.lee203@gmail.com




Fig. 1 | Geographic distribution of 2021 SenNet awards focused on mapping SnCs in human tissues. TMCs, RFA-RM-21-008 U54; TDA sites, RFA-RM-21-009 UG3/UH3; CODCC, RFA-RM-21-010 U24. Bold font identifies institutes of contact principal investigators.

Senolytics have proven efficacious in preclinical models of frailty, cardiovascular disease, kidney disease, diabetes, osteoarthritis, osteoporosis, hepatic and pulmonary fibrosis, steatosis, obesity, depression, mortality due to betacoronavirus infection and Alzheimer's disease^{27,28}. There are numerous ongoing clinical trials testing senolytics in age-related diseases and geriatric syndromes, including frailty, idiopathic pulmonary fibrosis, Alzheimer's disease, chronic kidney disease, osteoporosis and coronavirus disease 2019. Preliminary data suggest that the senolytic cocktail dasatinib plus quercetin is safe in humans and reduces SnC burden^{29,30}. In mice, a short course of senolytics, administered intermittently, is sufficient to improve multiple measures of physical fitness, even if administered late in life³¹, highlighting the immense potential impact of senotherapy on human health and healthcare costs.

Despite this promise of SnCs as a therapeutic target, there is sparse information about the identity and features of SnCs in human tissues. Little is known about where and when SnCs arise in humans or the extent of SnC and SASP heterogeneity *in vivo*. Such knowledge could guide therapeutic and organ-specific targeting of SnCs. Clearly, there is a compelling need to develop tools to map and identify human SnCs with spatial and temporal resolution. To address this need, the SenNet Consortium was created in 2021. The goal of SenNet is to functionally characterize the heterogeneity of SnCs in 18 tissues from healthy humans across lifespan at the single-cell resolution, using mice and other models and perturbations for validation. The scientific foundation for this approach is that aging is thought to begin at conception³². Furthermore, SnCs accumulate with chronological age even in the absence of a disease³³. Thus, characterizing SnCs across healthy lifespan informs geroscience, the study of fundamental biology of aging enabling identification of therapeutic targets for new interventions that could simultaneously prevent, attenuate and/or delay multiple age-related diseases, for which old age is by far the greatest risk factor³⁴. This approach will also facilitate the discrimination of SnCs that are physiological versus pathological (that is, required for establishing or reattaining tissue homeostasis versus driving or exacerbating disease), while informing future studies of the specific role of SnCs in individual diseases. The approach comes with risks, as there are no reference or control samples. Hence, perturbations that drive

or eliminate SnCs will be necessary for confirming SnC identity in healthy tissues.

A key product of SenNet will be multimodal atlases mapping these rare cells in human and mouse organs. Ancillary, albeit impactful, anticipated products will be new technologies to detect, quantify and trace SnCs, as well as biomarkers of SnCs that facilitate translation of senotherapy and diagnostics of the numerous chronic diseases in which SnCs have a causal role. To achieve this ambitious goal, several key deliverables are defined for the consortium (see section below). The goal of this Perspective is to define the rationale for SenNet, the approach of the consortium and the anticipated products.

Establishment of SenNet

Key impetuses for aspiring to map SnCs in human tissues are: (1) emerging roles for SnCs in maintaining tissue homeostasis and healing; (2) extensive evidence implicating SnCs in numerous, common age-related diseases, geriatric syndromes and frailty; (3) the advent of a relatively new class of drugs termed senotherapy with broad potential applications to improve human health once refined to more-specific SnC targets; and (4) recent advances in single-cell technologies that enable human tissue mapping efforts at unprecedented resolution, making the mapping of SnCs feasible.

To date, human SnCs have largely been characterized *in vitro*. This research revealed that SnC features depend on the cell type, senescence inducer, temporal dynamics and physiological context. This vast heterogeneity makes it challenging to identify and canonize SnC biomarkers. Thus, no single laboratory, research award or approach can comprehensively define cellular senescence. Yet, this is urgently needed if we are to harness knowledge of SnCs to benefit human health. The tissues, diseases and conditions that affect SnCs during aging and other physiological processes support the need for a community-wide scientific effort. The National Institutes of Health (NIH) Common Fund is a unique and exciting space at NIH specifically designed to address large challenges and opportunities that are of high priority for the entire NIH (all 27 institutes, centers and offices) and biomedical community.

The NIH Common Fund has rapidly mobilized new single-cell and spatial technologies to tackle other large, multidisciplinary and




Fig. 2 | Organs in which SnCs will be mapped by SenNet. Human tissues in which SnCs will be identified and characterized by the SenNet Consortium to produce 4D atlases of senescence across the lifespan of humans.

complex biomedical challenges, creating new platforms and tools for the broad scientific community that have tremendous potential to advance human health. The NIH Common Fund is managed by the Office of Strategic Coordination within the Division of Program Coordination, Planning and Strategic Coordination Office of the NIH Director. Common Fund programs must address emerging scientific opportunities and pressing challenges in biomedical research that are transformative, catalytic, synergistic, cross-cutting and unique. Examples of these initiatives include the Human Biomolecular Atlas Program³⁵, and Somatic Cell Genomic Editing³⁶, 4D Nucleome³⁷ and the Genotype-Tissue Expression project³⁸.

In 2021, the NIH Common Fund launched the SenNet program to catalyze the development of a framework for mapping SnCs and their SASP at single-cell resolution in healthy human tissues across development through physiological aging. This comprehensive blueprint for characterizing and mapping SnCs was initiated through several NIH-sponsored workshops engaging internal and external experts working across numerous disciplines. Participants concluded that there is a critical need to develop novel tools and technologies to identify SnCs *in vivo* and to harmonize data and SnC definitions across laboratories. Model systems and perturbations to validate characteristics of SnCs discovered in tissues were also deemed critical³⁹. For example, mice enable genetic and pharmacologic manipulations of SnCs (production and elimination) as well as longitudinal assessments as organisms chronologically age. In the fall of 2022, SenNet incorporated mechanisms to also establish a murine atlas of SnCs to help to inform the human atlas.

The initial 5-year investment of about \$190 million was awarded to eight tissue mapping centers (TMCs), seven technology development and application (TDA) sites and one consortium organization and data coordinating center (CODCC; housed across five sites) to integrate the data developed by the consortium (Fig. 1). The murine effort added five additional TMCs and five TDA sites. SenNet is purposely designed to have a single CODCC to harmonize and integrate efforts from all sites and awardees to create atlases of SnCs that capture information about the evolution of senescence in space and time (four-dimensional (4D) atlases) across the human life course. Eighteen tissues are currently covered by SenNet (Fig. 2).

TMCs are responsible for all aspects of data generation from tissue collection and analysis to data integration and interpretation. We anticipate that TMCs will acquire and integrate imaging and omics data to benchmark, standardize and validate SnC maps at single-cell resolution for their assigned tissues. The TDA sites are responsible for development of innovative, new approaches and tools necessary to deeply phenotype SnCs in human tissues and model systems. Examples include multi-omics characterization of the 4D nucleome in SnCs, high-throughput quantification of telomere-associated foci, and *in vivo* detection of SnCs via positron emission tomography imaging. Once developed, these new technologies are expected to be applied broadly and collaboratively across multiple tissues by the TMCs. The CODCC will collect, store and curate all data and metadata generated by the TMCs and TDA sites. The CODCC is responsible for generating the computational models, and final atlas products as well as the tools to visualize and disseminate the data as a resource for the broad scientific community.

It is expected that SenNet will interface with other cell mapping programs such as Human Bimolecular Atlas Program (HuBMAP), Human Cell Atlas (HCA) and the Kidney Precision Medicine Project (KPMP). HuBMAP is an NIH Common Fund Initiative to develop the resources and framework to map the >30 trillion cells that make up the human body using protein identifiers of cell lineage. HCA is using single-cell and spatial transcriptomics to create cell reference maps defining the position, function and characteristics of all cells in the human body. The KPMP is an initiative of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) aimed at using state-of-the-art and emerging technologies to characterize renal biopsies from participants with acute kidney injury or chronic kidney disease to enable personalized approaches to their treatment. Interfacing with these existing (and future) cell mapping initiatives will save extraordinary amounts of time and money (for example, using antigens and antibodies validated by HuBMAP to identify SnCs lineage). It will also add immense value if datasets use common descriptors to define cell subsets and the datasets can be integrated (for example, information on renal SnCs can be integrated with KPMP data on diseased tissue to advance diagnostic and therapeutic approaches). Ideally, the atlases generated by SenNet can be ‘layered’ on top of atlases of cell types in organs in healthy and diseased tissues generated by other mapping programs. Hence, structurally, the SenNet CODCC is similar to and cross-pollinates other NIH-sponsored cell mapping initiatives.

Characterization of senescent cells

Currently, no SnC-specific biomarker exists. Hence, the first goal of SenNet is to explore and define SnC biology. To address this challenge, SenNet created a Biomarker Working Group, which is responsible for iteratively compiling lists of cell traits, RNAs, proteins, lipids and metabolites that may be used to identify SnCs. This will enable modeling and annotating SnC classes and possibly subclasses that are anticipated to be dictated by cell origin, senescence inducer, tissue environment and human age. The overall goal of the Biomarker Working Group is to curate a database of senescence-associated biomarkers. The short-term goal is to generate a list of senescence-associated biomarkers currently used by members of the SenNet Consortium. The information collected will include cell type, the combinations in which biomarkers occur within a single cell, reagents used for detection (for example, antibodies or nucleic acid probes) and their compatibility with various experimental approaches and human tissues. The list is expected to evolve over time, with some markers being removed owing to lack of specificity or sensitivity, and others being added as our understanding of the senescent phenotype improves. As data collection ramps up, artificial intelligence will undoubtedly be crucial for refining the biomarker list. Ultimately, the Biomarker Working Group will produce a compendium of senescence biomarkers at the tissue and cell-type level. Our prediction is that multiple overlapping, non-static signatures of SnCs will ultimately be identified that require detection and quantification of more than one type of biomolecule, making it challenging to detect SnCs by a single method.

The complexity of senescence entails kinetic alterations in almost all aspects of cell biology, from epigenetic remodeling⁴⁰ to changes in the quantity and function of organelles⁴¹. In vitro studies of oncogene-induced senescence, replication-induced senescence and genotoxin-induced senescence revealed several, frequently generalizable characteristics of SnCs. To date, three main phenotypes characterize SnCs, with the caveat that they are context dependent. Generally, SnCs (1) enter an essentially permanent arrest of proliferation; (2) become relatively resistant to cell death; and (3) develop the SASP. Current biomarkers used to identify SnCs include increased expression of the cell cycle regulators *p16^{INK4a}* (ref. ⁴²) and *p21^{CIP1}* (ref. ⁴³), increased lysosomal senescence-associated β-galactosidase activity⁴⁴, decreased lamin B1 (ref. ⁴⁵), increased secretion of HMGB1 (ref. ⁴⁶) and several




Fig. 3 | Overview of technologies that will be implemented and developed by SenNet Consortium scientists to detect, characterize and spatially map the location of SnCs. CyTOF, cytometry by time-of-flight; scCITE-seq, cellular indexing of transcriptomes and epitopes by sequencing; sc/snRNA-seq, single-cell or single-nucleus RNA sequencing; snATAC-seq, single-nucleus assay for transposase-accessible chromatin using sequencing; MINA, multiplexed imaging of nucleome architectures; IMC, imaging mass cytometry; CODEX, co-detection by indexing immunofluorescence; DBiT-seq, deterministic barcoding in tissue for spatial-omics sequencing for co-mapping mRNAs and proteins; RNAScope, RNA in situ hybridization visualization of single molecules; MERFISH, multiplexed error-robust fluorescence in situ hybridization; GeoMx, NanoString GeoMx digital spatial profiling; Visium, Visium 10x Genomics molecular profiling; Seq-Scope, a spatial barcoding technology with spatial resolution comparable to optical microscopy; Pixel-seq, polony-indexed library sequencing.

markers of genotoxic stress including senescence-associated DNA damage foci of γH2AX and 53BP1, telomere-associated or telomere dysfunction-induced foci characterized by DNA damage response foci at telomeres⁴⁷, senescence-associated heterochromatic foci characterized by colocalization of dense DAPI staining and modified histones, and senescence-associated distensions of satellite DNA characterized by CENP-B foci at centromeres. Ideally, an endpoint associated with each of the three main phenotypes should be measured to determine if a cell is senescent. Relying on a single endpoint is fraught with error. For example, high senescence-associated β-galactosidase activity is detected in cultured confluent fibroblasts^{48,49} and certain activated macrophages^{50,51}, whereas *p16^{INK4a}* and *p21^{CIP1}* expression can be induced in a reversible manner under certain physiological contexts^{50–54}.

In addition to the above SnC biomarkers, activation of LINE-1 retrotransposable elements^{55,56}, cytoplasmic chromatin fragments⁵⁷ and mitochondrial DNA⁵⁸ are detected in SnCs. Numerous other molecules are attributed to SnCs or the SASP. However, in the absence of cross-validation with established SnC biomarkers at single-cell resolution and validation with appropriate perturbations provoking or targeting SnCs, these molecules are only potential biomarkers of SnCs. As more cell types and physiological contexts are studied, a universal senescence-specific marker may never emerge. Regardless, deep characterization and localization of SnCs *in vivo* will advance options for diagnosis and treatment of multiple diseases of old age. Internal and external collaborations are an important part of SenNet to facilitate adaptation of emerging technologies and cross-validation. Hence, it is difficult to define the entire scope of features that will ultimately constitute SnC signatures.

Key challenges lie ahead. As stated, none of the current SnC biomarkers are specific to SnCs, requiring multimodal measurement of multiple endpoints at the single-cell level just to identify SnCs^{1,59}, let alone characterize them further. Most published studies rely on bulk tissue analysis or, if at single-cell resolution, implement one method




Fig. 4 | Overview of the visualization tools to be developed to enable exploration of the senescent cell atlases produced by SenNet. CCF exploration user interface (EUI) and Vitessce (a visual integration tool for exploring spatial single-cell datasets) will be integrated to enable seamless navigation across scales and queries of SenNet data. The CCF EUI enables registered tissue blocks from the registration user interface (RUI) to be explored

spatially (via body browser in the left screenshot, center) and using ontology terms (via hierarchy in the left screenshot, on left) at anatomic scale. A click on a tissue dataset (left) leads to Vitessce (right), which supports the exploration of cellular and molecular scale distributions. EUI provides clinical and spatial context and ontology cross-links, while Vitessce supports details on demand at the molecular scale.

to measure one type of biomolecule. Neither approach is adequate to precisely identify SnCs in tissues, let alone their lineage, their unique characteristics and to predict their role in physiological aging. Multiple targeted and unbiased approaches are required (Fig. 3 and see Supplementary Information for method details) and integration of multi-omics data will be necessary to achieve the goals set forth by SenNet. Considerable value is added by comparing and contrasting characteristics of SnCs of similar or distinct lineages across tissues to discover common (for example, increased expression of a cell cycle inhibitor) and unique (for example, increased expression of a particular SASP protein) SnC features as potential biomarkers and molecular targets. This emphasizes the need for a trans-NIH effort and justifies the structure of SenNet (for example, multi-site, multi-platform, technology development, and a single-data integration site).

Senescent cell atlas

Creating a multiorgan 4D atlas of SnCs with healthy human aging will yield an important tool for investigating disease mechanisms relevant to the mission of most NIH institutes and centers. Currently, we have no knowledge as to whether different types of SnCs appear with advancing physiological age, and/or if SnC phenotypes evolve over time *in vivo*. Another possibility is that SnCs arise specifically because of acute tissue injury or disease but immune clearance of SnCs declines with age, precipitating chronic disease. Indeed, preexisting SnCs impair host responses to tissue injury or infection⁵, thereby promoting disease in a feed-forward mechanism.

Single-cell technologies for imaging and deep phenotyping of SnCs have tremendous clinical and translational potential. Complementary, multimodal characterization of SnCs will not only deepen our understanding of senescence biology in health but also reveal the clinical significance of SnCs in cancer, fibrosis, metabolic disorders and diverse degenerative diseases. As bioinformatics approaches on multi-omics are evolving, it will be possible to integrate all epigenomics data with cellular composition for identification of SnC phenotypes. The SenNet Consortium is geared toward deconvoluting the cellular senescence phenotypes based on bioinformatic multi-omics approaches. Although the current goal of SenNet is the mapping of SnCs in ‘normal/healthy’ human and murine tissues to generate reference atlases of SnCs, we anticipate future efforts will leverage these data to study the role of SnCs in various human pathologies.

Given the multiorgan and multimodal data generation envisioned, a structured, cross-team data management, organization and analysis

plan is essential. The SenNet CODCC will manage data curation, integration, analysis, atlas creation and dissemination through the SenNet Data Portal (Fig. 4). These harmonization and integration efforts will be coordinated with the Common Fund Data Ecosystem to align SenNet for integration with data from other Common Fund programs. Uniformly processed molecular and cellular data will be integrated with the common coordinate framework (CCF) and will be the basis for construction of an atlas of SnCs. To facilitate uniform data processing and quality-control pipelines within CODCC, and reuse by other data consumers, CODCC will mandate data submission using common data formats that are aligned with CCF reference atlas construction. Examples are the use of Azimuth for cell-type annotation or validated organ mapping antibody panels (OMAP). Uniform processing pipelines will implement state-of-the-art algorithms for the analysis of imaging, sequencing and multi-omics, which will generate standardized datasets that are spatially registered, segmented and annotated using CCF ‘Anatomical Structures, Cell Types and Biomarkers’ (ASCT + B) terminology and hence linked to existing ontologies. Integrated and harmonized datasets will be made available through the data portal, along with the raw data.

The SenNet Data Portal will also integrate the CCF Registration User Interface (CCF RUI), CCF Explorer User Interface (CCF EUI) and the Vitessce framework in support of exploratory visualization of existing data across levels—from the whole body to single organs to molecular-level and cellular-level datasets and vice versa (Fig. 4). Clinical data will also be standardized and shared in an extension of the CODCC and CCF efforts and will be the basis for standardized implementation and association with electronic health record clinical data in the future.

The CCF consists of ontologies, libraries and computer-based and other training materials that support the efficient mapping, registration and exploration of clinically, semantically and spatially indexed human tissue data. SenNet will extend the HuBMAP CCF that consists of: (1) a CCF Specimen Ontology, which provides CCF-relevant demographic and clinical metadata about the specimen and donor (the ‘who’); (2) a CCF Biological Structure Ontology, which describes ‘what’ part of the body a tissue sample came from; and (3) a CCF Spatial Ontology, which indicates ‘where’ the tissue is in a three-dimensional (3D) reference system. In addition, the CCF defines a ‘registration process’ that makes it possible to annotate data and map it to the 3D reference system, as well as an ‘exploration process’, which facilitates query, analysis and visual examination of registered tissue data and prediction of properties (for example, what cell types are commonly located




Fig. 5 | Schematic of the SenNet Consortium goals. SnC atlas building requires a framework for layering data. Data generated by the TMCs and TDA sites are input into the CODCC along with associated metadata. The datasets are organized and de-identified (curation), then analyzed and integrated. The goal is to create an atlas and public database of curated data that can be searched, analyzed and visualized as 3D images of organs using unified annotations. High-quality experimental data are needed to create a human reference atlas. The evolving reference atlas supports data standardization and federation, making it possible to integrate data from different specimens, laboratories and assay types. The atlas characterizes the healthy human—from the whole body down to the single-

cell level; it can be compared across ages and diseases to understand differences, advance research and improve human health. Use case scenarios for different stakeholders (researchers, practitioners and students) guide atlas construction and usage but also experimental data acquisition and analysis. Of note, diversity in terms of human participant gender, race and socioeconomic status is emphasized in SenNet. However, these variables may impact SnC heterogeneity even further, meaning that, in the timeframe of the initial grants, statistically meaningful characterization of SnCs across diverse populations might not be achieved.

in a specific anatomical structure or what antibodies should be used to identify a desired set of protein biomarkers) (Fig. 4).

The CCF also provides 3D representations of anatomy linked to ASCT + B tables⁶⁰. Note that the CCF is semantically explicit (that is, terminology for anatomical structures, cell types and biomarkers link to existing ontologies, namely Uberon/Foundation Model of Anatomy, Cell Ontology(CL) and HUGO Gene Nomenclature Committee) as well as spatially explicit (for example, 3D reference organs are used for registration and exploration). In February 2022, there were ASCT + B tables for 25 organs and 50 associated 3D reference object sets (1–4 per organ, for example, 1 uterus but 4 kidneys to capture left–right and male–female versions), which represent the size, shape, position and spatial orientation of major anatomical structures in an organ-specific manner. The ASCT + B tables and associated spatial reference objects represent the human body in a simplified manner as a partonomy where each cell is part of an anatomical structure that is part of larger anatomical structures and ultimately makes up the entire body.

The SenNet CCF Atlas and SenNet CODCC Data Portal will serve as the ‘hub’ for data coordination and integration. Future extensions of the CCF will require integrating specimen ontology with clinical informatics and electronic health record-based clinical data to characterize not only the state of the participant when the biospecimen was acquired, but also the evolution of the person over their entire lifetime. Furthermore, this may serve as an integration point for environmental factors or cumulative drug exposures. Such examples may then be used to interpret an individual’s ‘health’ atlas using artificial intelligence platforms.

Challenges to creating a 4D SnC atlas include: (1) SnCs are rare in vivo; (2) spatial-omics is a nascent technology implying an additional burden of validation for ill-characterized cell types such as SnCs; (3) for any single SnC biomarker, it is not yet established whether changes in mRNA, protein or the epigenome (or a combination) best reflect a senescent state; (4) implementing a biomarker panel that includes a combination of proteins, nucleic acids, morphology markers and measure of enzymatic activity endpoints currently limits the ability to colocalize SnC biomarkers at single-cell resolution; (5) SnCs in different tissues will probably express common as well as tissue-specific patterns of senescence features; and (6) a lack of tools to confidently discriminate pathological versus physiological SnCs. In complex tissues, both the physiological and pathological roles of SnCs may occur in close proximity (for example, chronic tissue damage foci with adjacent areas of tissue regeneration). To optimize senotherapy and minimize side effects of this new class of drugs, one would like to distinguish between SnCs involved in these two processes and to do so using a biomarker measured in an easily accessed tissue or biofluid. This will require tissue mapping advances as well as biomarker discovery in human biofluids.

SenNet deliverables

To produce comprehensive and high-resolution atlases of SnCs, several key SenNet deliverables are anticipated (Fig. 5). First, production of extensive multi-omics and imaging datasets that functionally and spatially identify and characterize SnCs at the single-cell level in 18 human tissues across the life course of humans. The datasets will be made readily accessible to the broad scientific community and searchable.

Innovative visualization tools will be developed to maximize the value and accessibility of the data. Second, mapping rare and heterogeneous SnCs in human tissues will require the generation of new tools, technologies and computation modeling systems. Third, the data will yield biomarker panels that enable the identification of SnCs, define their secretome, and illustrate the common principles and heterogeneity of SnCs in the human body. Fourth, validation of SnC biomarkers will require establishing reliable approaches for perturbing SnCs (eliminating, modifying and removing SnCs). Finally, improved imaging tools will be needed to rigorously identify SnCs and their unique properties *in vivo*, with the aspirational goal of ultimately being able to do so longitudinally at the whole-organism level. The ability to detect SnCs noninvasively and longitudinally in people would substantially improve our ability to monitor the effects of injury, inflammation, carcinogenesis, autoimmunity and responsiveness to specific drugs or biologics, ultimately identifying those who may benefit from senotherapies.

A clear and comprehensive definition of SnCs in multiple organs will enable identification of molecular targets unique or enriched in SnCs that could form the basis of selective senotherapeutics to advance the treatment of senescence-related pathologies. Biomarkers will ideally be validated within and across tissues, ultimately enabling predictive modeling, optimizing SnC targeting and ensuring the safety and efficacy of senotherapeutics. A deeper, temporal understanding of SnCs with physiological aging will enable the development of therapies that promote the beneficial effects of SnCs while suppressing or removing the deleterious effects.

The timelines for the development of these key deliverables are as follows. During year 1 (mid-2021 to mid-2022), the consortium will establish policies and guidelines to facilitate collaboration, harmonization and rigor of SenNet activities. Working groups will be established to inform consortium-wide activities and facilitate interfacing with other cell mapping initiatives. These include working groups on policy, benchmarking, biomarkers, omics mapping, imaging, data submission, CCF, Common Fund data ecosystem integration, publication and outreach. The working groups reflect every aspect of the SenNet project pipeline from setting standards for high-quality data generation, annotation and integration in a standardized format, to data dissemination and visualization. In years 2–5 of the consortium (mid-2022 to mid-2026), TMCs are expected to regularly generate large volumes of multi-omics and imaging data, and to develop two-dimensional maps of SnCs in human and mouse tissues. This will require collaborations between TMCs, and with TDA sites, to validate detection tools and methods, and to determine the extent of variability in SnC abundance and features between tissues and individuals across the aging process. As data are generated, the CODCC will create a framework for depositing and visualizing the data in four dimensions. It is expected that the CODCC will release datasets regularly for peer review, publication and sharing. As an example, the first release of data from HubMAP comprised data and metadata from de-identified donors for seven tissues. This included >300 datasets defining the tissue samples and data generated from them via microscopy, mass spectrometry, sequencing and other modalities. Future data releases are scheduled biannually.

Concluding remarks

SenNet's vision is to identify and functionally characterize the heterogeneity of SnCs across numerous human tissues at single-cell resolution, from embryonic development through to physiological aging. Novel technologies and tools will be created and applied to the characterization of human SnCs. Perturbations and studies in mice will be used to validate new SnC biomarkers. Generating SnC atlases via a collaborative consortium, integrating the data through a single-data coordinating center, and harmonizing this effort with other cell mapping initiatives will amplify the value of SenNet. This NIH Common Fund effort will undoubtedly pave the way for exciting, new possibilities in

understanding and therapeutically modulating senescence-associated human conditions.

Future perspectives

SenNet will serve as a unique and comprehensive resource to elucidate the heterogeneity of SnCs elicited in different cell types, by different drivers of senescence, anatomical location and human age. Ideally, novel biomarkers to identify SnCs and distinct signatures of disease-specific and beneficial SnCs will be discovered. The knowledge gained can be deployed to better understand the role of SnCs in health and disease, and to guide clinical translation of senotherapeutics. New biomarkers of SnCs are anticipated to be valuable for identifying individuals at risk of disease, stratifying participants in interventional studies, monitoring the response to senotherapeutics, evaluating therapeutic efficacy and ultimately optimizing and personalizing interventions.

References

1. Gorgoulis, V. et al. Cellular senescence: defining a path forward. *Cell* **179**, 813–827 (2019).
2. Kirkland, J. L. & Tchkonia, T. Cellular senescence: a translational perspective. *EBioMedicine* **21**, 21–28 (2017).
3. Niedernhofer, L. J. et al. Nuclear genomic instability and aging. *Annu. Rev. Biochem.* **87**, 295–322 (2018).
4. Bussian, T. J. et al. Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. *Nature* **562**, 578–582 (2018).
5. Camell, C. D. et al. Senolytics reduce coronavirus-related mortality in old mice. *Science* <https://doi.org/10.1126/science.abe4832> (2021).
6. Chang, J. H. et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. *Nat. Med.* **22**, 78–83 (2016).
7. Musi, N. et al. Tau protein aggregation is associated with cellular senescence in the brain. *Aging Cell* <https://doi.org/10.1111/acel.12840> (2018).
8. Ogródniak, M. et al. Cellular senescence drives age-dependent hepatic steatosis. *Nat. Commun.* <https://doi.org/10.1038/ncomms15691> (2017).
9. Yousefzadeh, M. J. et al. An aged immune system drives senescence and ageing of solid organs. *Nature* **594**, 100–105 (2021).
10. Zhang, P. S. et al. Senolytic therapy alleviates a beta-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer's disease model. *Nat. Neurosci.* **22**, 719–728 (2019).
11. Kennedy, B. K. et al. Geroscience: linking aging to chronic disease. *Cell* **159**, 708–712 (2014).
12. Basisty, N. et al. A proteomic atlas of senescence-associated secretomes for aging biomarker development. *PLoS Biol.* <https://doi.org/10.1371/journal.pbio.3000599> (2020).
13. Coppe, J. P. et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. *PLoS Biol.* **6**, 2853–2868 (2008).
14. Schafer, M. J. et al. The senescence-associated secretome as an indicator of age and medical risk. *JCI Insight* <https://doi.org/10.1172/jci.insight.133668> (2020).
15. Ovadysa, Y. et al. Impaired immune surveillance accelerates accumulation of senescent cells and aging. *Nat. Commun.* <https://doi.org/10.1038/s41467-018-07825-3> (2018).
16. Demaria, M. et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. *Dev. Cell* **31**, 722–733 (2014).
17. Wiley, C. D. et al. SILAC analysis reveals increased secretion of hemostasis-related factors by senescent cells. *Cell Rep.* **28**, 3329–3337 (2019).

18. Baker, D. J. et al. Clearance of p16^{Ink4a}-positive senescent cells delays ageing-associated disorders. *Nature* **479**, 232–236 (2011).
19. Baker, D. J. et al. Naturally occurring p16^{Ink4a}-positive cells shorten healthy lifespan. *Nature* **530**, 184–189 (2016).
20. Zhu, Y. et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. *Aging Cell* **14**, 644–658 (2015).
21. Wang, Y. Y. et al. Discovery of piperlongumine as a potential novel lead for the development of senolytic agents. *Aging* **8**, 2915–2926 (2016).
22. Yousefzadeh, M. J. et al. Fisetin is a senotherapeutic that extends health and lifespan. *EBioMedicine* **36**, 18–28 (2018).
23. Zhu, Y. et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. *Aging Cell* **15**, 428–435 (2016).
24. Baar, M. P. et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. *Cell* **169**, 132–147 (2017).
25. He, Y. H. et al. Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity. *Nat. Commun.* <https://doi.org/10.1038/s41467-020-15838-0> (2020).
26. Amor, C. et al. Senolytic CAR T cells reverse senescence-associated pathologies. *Nature* **583**, 127–132 (2020).
27. Childs, B. G. et al. Senescent cells: an emerging target for diseases of ageing. *Nat. Rev. Drug Discov.* **16**, 718–735 (2017).
28. Niedernhofer, L. J. & Robbins, P. D. Senotherapeutics for healthy ageing. *Nat. Rev. Drug Discov.* **17**, 377 (2018).
29. Hickson, L. J. et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. *EBioMedicine* **47**, 446–456 (2019).
30. Justice, J. N. et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. *EBioMedicine* **40**, 554–563 (2019).
31. Xu, M. et al. Senolytics improve physical function and increase lifespan in old age. *Nat. Med.* **24**, 1246–1256 (2018).
32. Milne, E. M. When does human ageing begin? *Mech. Ageing Dev.* **127**, 290–297 (2006).
33. Yousefzadeh, M. J. et al. Tissue specificity of senescent cell accumulation during physiologic and accelerated aging of mice. *Aging Cell* **19**, e13094 (2020).
34. Martin, G. M. Geroscience: addressing the mismatch between its exciting research opportunities, its economic imperative and its current funding crisis. *Exp. Gerontol.* **94**, 46–51 (2017).
35. Hu, B. C. The human body at cellular resolution: the NIH Human Biomolecular Atlas Program. *Nature* **574**, 187–192 (2019).
36. Saha, K. et al. The NIH somatic cell genome editing program. *Nature* **592**, 195–204 (2021).
37. Dekker, J. et al. The 4D nucleome project. *Nature* **549**, 219–226 (2017).
38. Consortium, G. T. The Genotype-Tissue Expression (GTEx) project. *Nat. Genet.* **45**, 580–585 (2013).
39. Roy, A. L. et al. A blueprint for characterizing senescence. *Cell* **183**, 1143–1146 (2020).
40. Parry, A. J. & Narita, M. Old cells, new tricks: chromatin structure in senescence. *Mamm. Genome* **27**, 320–331 (2016).
41. Correia-Melo, C. et al. Mitochondria are required for pro-ageing features of the senescent phenotype. *EMBO J.* **35**, 724–742 (2016).
42. Liu, Y. et al. Expression of p16^{Ink4a} in peripheral blood T cells is a biomarker of human aging. *Aging Cell* **8**, 439–448 (2009).
43. Wang, B. et al. An inducible p21-Cre mouse model to monitor and manipulate p21-highly-expressing senescent cells in vivo. *Nat. Aging* **1**, 962–973 (2021).
44. Dimri, G. P. et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. *Proc. Natl Acad. Sci. USA* **92**, 9363–9367 (1995).
45. Freund, A., Laberge, R. M., Demaria, M. & Campisi, J. Lamin B1 loss is a senescence-associated biomarker. *Mol. Biol. Cell* **23**, 2066–2075 (2012).
46. Davalos, A. R. et al. p53-dependent release of Alarmin HMGB1 is a central mediator of senescent phenotypes. *J. Cell Biol.* **201**, 613–629 (2013).
47. Hewitt, G. et al. Telomeres are favoured targets of a persistent DNA damage response in ageing and stress-induced senescence. *Nat. Commun.* **3**, 708 (2012).
48. Leontieva, O. V. & Blagosklonny, M. V. Gerosuppression in confluent cells. *Aging* **6**, 1010–1018 (2014).
49. Severino, J., Allen, R. G., Balin, S., Balin, A. & Cristofalo, V. J. Is beta-galactosidase staining a marker of senescence in vitro and in vivo? *Exp. Cell. Res.* **257**, 162–171 (2000).
50. Hall, B. M. et al. p16^{Ink4a} and senescence-associated beta-galactosidase can be induced in macrophages as part of a reversible response to physiological stimuli. *Aging* **9**, 1867–1884 (2017).
51. Hall, B. M. et al. Aging of mice is associated with p16^{Ink4a}- and beta-galactosidase-positive macrophage accumulation that can be induced in young mice by senescent cells. *Aging* **8**, 1294–1315 (2016).
52. Aix, E., Gutierrez-Gutierrez, O., Sanchez-Ferrer, C., Aguado, T. & Flores, I. Postnatal telomere dysfunction induces cardiomyocyte cell-cycle arrest through p21 activation. *J. Cell Biol.* **213**, 571–583 (2016).
53. Puente, B. N. et al. The oxygen-rich postnatal environment induces cardiomyocyte cell-cycle arrest through DNA damage response. *Cell* **157**, 1243–1243 (2014).
54. Tane, S. et al. CDK inhibitors, p21^{Cip1} and p27^{Kip1}, participate in cell cycle exit of mammalian cardiomyocytes. *Biochem. Biophys. Res. Commun.* **443**, 1105–1109 (2014).
55. De Cecco, M. et al. Transposable elements become active and mobile in the genomes of aging mammalian somatic tissues. *Aging* **5**, 867–883 (2013).
56. De Cecco, M. et al. L1 drives IFN in senescent cells and promotes age-associated inflammation. *Nature* **566**, 73–78 (2019).
57. Dou, Z. et al. Cytoplasmic chromatin triggers inflammation in senescence and cancer. *Nature* **550**, 402–406 (2017).
58. Campisi, J. et al. From discoveries in ageing research to therapeutics for healthy ageing. *Nature* **571**, 183–192 (2019).
59. Sharpless, N. E. & Sherr, C. J. Forging a signature of in vivo senescence. *Nat. Rev. Cancer* **15**, 397–408 (2015).
60. Borner, K. et al. Anatomical structures, cell types and biomarkers of the Human Reference Atlas. *Nat. Cell Biol.* **23**, 1117–1128 (2021).

Acknowledgements

This research is supported by the NIH Common Fund, through the Office of Strategic Coordination/Office of the NIH Director under awards: U54AG075932 (to J.C. and B.S.), UG3CA268112 (to H.D.-L.), U54AG075934 (to L.D. and F.C.), UG3CA268117 (to Z.D.), U54AG076043 (to R.F. and S.H.), U54AG075931 (to T.F., M.K., A.L.M., O.E., M.R. and I.R.), UG3CA268096 (to L.G.), U54AG075941 (to G.K., V.G., N.M. and P.R.), UG3CA268091 (to J.H.L.), U54AG075936 (to P.J.L.), UG3CA268105 and U54AG075932 (to S.M.), UG3CA268202 (to N.N., S.W. and J.M.), U54AG076041 (to L.J.N. and C.F.A.), UG3CA268103 (to J.F.P.), U54AG076040 (to H.P.) and U24CA268108 (to J.C.S., Z.B.-J. and P.B.). We thank V. Bekker, SCENT Program Manager for administrative and formatting assistance. We also thank D. Mathias, Science Illustrator, for assistance with figures.

Author contributions

P.J.L., C.C.B., P.B., K.B., J.C., F.C., H.D.-L., P.D.J., L.D., F.E.D., O.E., R.F., T.F., D.F., V.G., N.G., C.G., I.H., Z.B.-J., P.K., S.K., M.K., G.K., H.L., J.H.L., J.M., Q.M., S.M., K.M., A.L.M., N.M., N.N., J.F.P., I.R., J.C.R.-M., P.R., M.R., A.L.R., M.S.-K., B.S., P.S., J.C.S., V.S., J.X., J.W., A.I.W. and L.N wrote the manuscript; P.J.L., K.B., N.G., R.F. and S.K generated the figures; P.J.L., K.B., A.L.R., S.K., V.B., L.J.N., J.F.P. and R.F. reviewed and/or edited the manuscript; P.J.L., J.C., A.L.R., S.K. and L.J.N. contributed to discussion and provided critical review and/or revision of the manuscript. All other co-authors outside the writing group reviewed the manuscript and approved of its submission for publication.

Competing interests

J.H.L. is an inventor on a pending patent applications related to Seq-Scope. L.G. is an inventor on two pending patent applications related to Pixel-seq. H.D.-L. has a research contract with MegaPro Biomedical and serves as managing director of a publishing company, Monasteria Press. R.F. is co-founder and scientific advisor of IsoPlexis, Singleron Biotechnologies and AtlasXomics. N.G. is a co-founder and equity owner of Datavisyn. J.C. receives research support from Ono, who are working on a new senolytic and have stock in Unity Biotechnology. The other authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s43587-022-00326-5>.

Correspondence should be addressed to Patty J. Lee.

Peer review information *Nature Aging* thanks Piero Carninci and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

© Springer Nature America, Inc. 2022

Writing Group

Patty J. Lee¹✉, Christopher C. Benz², Philip Blood³, Katy Börner⁴, Judith Campisi², Feng Chen⁵, Heike Daldrup-Link⁶, Phil DeJager⁷, Li Ding⁸, Francesca E. Duncan⁹, Oliver Eickelberg¹⁰, Rong Fan¹¹, Toren Finkel¹², David Furman², Vesna Garovic¹³, Nils Gehlenborg¹⁴, Carolyn Glass¹⁵, Indra Heckenbach², Ziv-Bar Joseph¹⁶, Pragati Katiyar¹⁷, So-Jin Kim¹, Melanie Königshoff¹⁰, George A. Kuchel¹⁸, Haesung Lee¹⁹, Jun Hee Lee²⁰, Jian Ma²¹, Qin Ma²², Simon Melov², Kay Metis²³, Ana L. Mora²⁴, Nicolas Musi²⁵, Nicola Neretti²⁶, João F. Passos¹³, Irfan Rahman²⁷, Juan Carlos Rivera-Mulia²⁸, Paul Robson²⁹, Mauricio Rojas²⁴, Ananda L. Roy³⁰, Morten Scheibye-Knudsen³¹, Birgit Schilling², Pixu Shi³², Jonathan C. Silverstein²³, Vidyani Suryadevara⁶, Jichun Xie³², Jinhua Wang³³, A. Ian Wong¹ & Laura J. Niedernhofer²⁸

Brown University TDA

Nicola Neretti²⁶, Jian Ma²¹ & Siyuan (Steven) Wang³⁴

Buck Institute for Research on Aging TMC/TDA

Hannah Anvari⁹, Julia Balough², Christopher Benz², Joanna Bons², Boris Brenerman², Judith Campisi², Francesca E. Duncan⁹, William Evans³⁵, David Furman², Akos Gerencser², Heather Gregory³⁶, Malene Hansen², Indra Heckenbach², Jamie Justice³⁶, Pankaj Kapahi², Simon Melov², Natalia Murad², Amy O'Briain², Mary Ellen Pavone⁹, Mark Powell², Birgit Schilling², Gary Scott², Elisheva Shanes³⁷, Mahalakshmi Shankaran³⁵, Eric Verdin², Daniel Winer² & Fei Wu²

Consortium Organization and Data Coordinating Center (CODCC)

Andrew Adams³, Philip D. Blood³, Katy Börner⁴, Andreas Bueckle⁴, Ivan Cao-Berg³, Hao Chen¹⁶, Michael Davis²³, Shane Filus³, Nils Gehlenborg¹⁴, Yuhua Hao³⁸, Austin Hartman³⁸, Euxhen Hasanaj¹⁶, Jesse Helfer²³, Bruce Herr II⁴, Ziv Bar Joseph¹⁶, Kay Metis²³, Gesmira Molla³⁸, Gloria Mou³, Juan Puerto³, Ellen M. Quardokus⁴, Alexander J. Ropelewski³, Matt Ruffalo¹⁶, Rahul Satija³⁸, Melissa Schwenk²³, Robin Scibek³, William Shirey²³, Max Sibilla²³, Jonathan C. Silverstein²³, Joel Welling³ & Zhou Yuan²³

Columbia TMC

Richard Bonneau^{39,40}, Angela Christiano⁴¹, Benjamin Izar⁴², Vilas Menon⁴³, David M. Owens⁴⁴, Hemali Phatnani⁴³, Colin Smith⁴⁵, Yousin Suh⁴¹ & Andrew F. Teich⁴³

Duke University TMC

Valerie Bekker¹, Cliburn Chan³², Elias Coutavas¹, Carolyn Glass¹⁵, Matthew G. Hartwig⁴⁶, Zhicheng Ji³², So-Jin Kim¹, Haesung Lee¹⁹, Patty J. Lee¹, Andrew B. Nixon¹⁹ & A. Ian Wong¹

Massachusetts General Hospital TDA

Zhixun Dou⁴⁷, Jayaraj Rajagopal⁴⁷ & Nikolai Slavov⁴⁸

Mayo Clinic TDA

David Holmes III¹³, Diana Jurk¹³, James L. Kirkland⁴⁹, Anthony Lagnado¹³, João F. Passos¹³ & Tamara Tchkonia¹³

National Institute of Health (NIH)

Kristin Abraham⁵⁰, Amanda Dibattista⁵¹, Yih-Woei Fridell¹⁷, T. Kevin Howcroft⁵², Chamelli Jhappan⁵³, Pragati Katiyar¹⁷, Viviana Perez Montes¹⁷, Mercy Prabhudas⁵⁴, Haluk Resat⁵⁵, Ananda L. Roy³⁰ & Veronica Taylor³⁰

Stanford TDA

Heike Daldrup-Link⁶, Manoj Kumar⁶ & Vidyani Suryadevara⁶

University of Connecticut TMC

Francisco Cigarroa²⁵, Rachel Cohn¹⁸, Tiffany M. Cortes²⁵, Elise Courtois²⁹, Jeffrey Chuang²⁹, Monica Davé²⁹, Sergii Domanskyi²⁹, Elizabeth Ann Lieser Enninga¹³, Giray Naim Eryilmaz²⁹, Sara E. Espinoza²⁵, Vesna Garovic¹³, Jon Gelfond²⁹, James Kirkland⁴⁹, George A. Kuchel¹⁸, Chia-Ling Kuo¹⁸, Julia S. Lehman¹³, Cristina Aguayo-Mazzucato⁵⁶, Alexander Meves¹³, Nicolas Musi²⁵, João F. Passos¹³, Meenakshi Rani²⁵, Paul Robson²⁹, Shane Sanders²⁹, Tamara Tchkonia¹³, Asa Thibodeau²⁹, Stefan G. Tullius⁵⁷, Duygu Ucar²⁹, Brian White²⁹, Qian Wu¹⁸, Ming Xu¹⁸ & Seiji Yamaguchi²⁵

University of Michigan TDA

Naziheh Assarzadegan⁵⁸, Chun-Seok Cho²⁰, Irene Hwang²⁰, Yongha Hwang²⁰, Jun Hee Lee²⁰ & Jingyue Xi⁵⁹

University of Minnesota TMC

Oyedele A. Adeyi⁶⁰, Constantin F. Aliferis⁶¹, Alessandro Bartolomucci⁶², Xiao Dong⁶³, Mickayla J. DuFresne-To²⁸, Sayeed Ikramuddin⁶⁴, Steve G. Johnson⁶¹, Andrew C. Nelson⁶⁰, Nicola Neretti²⁶, Laura J. Niedernhofer²⁸, Xavier S. Revelo⁶², Juan Carlos Rivera-Mulia²⁸, Claudia Trevilla-Garcia²⁸, John M. Sedivy²⁶, Elizabeth L. Thompson²⁸, Paul D. Robbins²⁸ & Jinhua Wang⁶¹

University of Pittsburgh TMC

Katherine M. Aird⁶⁵, Jonathan K. Alder¹⁰, Delphine Beaulieu¹⁰, Marta Bueno¹⁰, Jazmin Calyeca²⁴, Julián A. Chamucero-Millaris²⁴, Stephen Y. Chan⁶⁶, Hao Chen¹⁶, Dongjun Chung²², Anthony Corbett^{67,68}, Oliver Eickelberg¹⁰, Toren Finkel¹², Vera Gorbunova⁶⁹, Kymberly M. Gowdy²⁴, Aditi Gurkar¹², Euxhen Hasanalj¹⁶, Jeffrey C. Horowitz²⁴, Qianjiang Hu¹⁰, Ziv-Bar Joseph¹⁶, Gagandeep Kaur²⁷, Timur O. Khaliullin²⁴, Melanie Königshoff¹⁰, Robert Lafyatis⁷⁰, Serafina Lanna¹², Dongmei Li⁶⁸, Anjun Ma²², Qin Ma²², Ana L. Mora²⁴, Alison Morris¹⁰, Thivanka M. Muthumalage²⁷, Victor Peters²⁴, Gloria S. Pryhuber²⁷, Irfan Rahman²⁷, Brenda F. Reader⁷¹, Mauricio Rojas²⁴, Lorena Rosas²⁴, John C. Sembrat¹⁰, Sadiya Shaikh²⁷, Hangchuan Shi⁶⁸, Sean D. Stacey⁷¹, Claudette St. Croix⁷², Cankun Wang²², Qixin Wang²⁷ & Andrew Watts⁶⁸

University of Washington TDA

Liangcai Gu⁷³, Yiing Lin⁷⁴, Peter S. Rabinovitch⁷⁵ & Mariya T. Sweetwyne⁷⁵

Washington University TMC

Maxim N. Artyomov⁷⁶, Samuel J. Ballentine⁷⁶, Feng Chen⁵, Milan G. Chheda⁸, Sherri R. Davies⁷⁷, Li Ding⁸, John F. DiPersio⁸, Ryan C. Fields⁷⁷, James A.J. Fitzpatrick^{78,79}, Robert S. Fulton⁸⁰, Shin-ichiro Imai⁸¹, Sanjay Jain⁵, Tao Ju⁸², Vladimir M. Kushnir⁸³, Daniel C. Link⁸, Michael Ben Major⁷⁹, Stephen T. Oh⁸⁴, Daniel Rapp⁷⁷, Michael P. Rettig⁸, Shelia A. Stewart⁷⁹, Deborah J. Veis^{76,85}, Kiran R. Vij⁸, Michael C. Wendl⁸ & Matthew A. Wyczalkowski⁸

Yale TMC

Rong Fan¹¹, Joseph E. Craft⁸⁶, Archibald Enninful¹¹, Negin Farzad¹¹, Peter Gershkovich⁸⁷, Stephanie Halene⁸⁸, Yuval Kluger⁸⁷, Jennifer VanOudenhoove⁸⁹, Mina Xu⁸⁷, Junchen Yang⁸⁷ & Mingyu Yang¹¹

¹Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University School of Medicine, Durham, NC, USA. ²Buck Institute for Research on Aging, Novato, CA, USA. ³Pittsburgh Supercomputing Center, Carnegie Mellon University, Pittsburgh, PA, USA. ⁴Department of

Intelligent Systems Engineering, School of Informatics, Computing, and Engineering, Indiana University, Bloomington, IN, USA. ⁵Department of Medicine, Division of Nephrology, Washington University in St. Louis, St. Louis, MO, USA. ⁶Stanford University, Stanford, CA, USA. ⁷Department of Neurology, Columbia University, New York, NY, USA. ⁸Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA. ⁹Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. ¹⁰Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. ¹¹Department of Biomedical Engineering, Yale University, New Haven, CT, USA. ¹²Aging Institute, University of Pittsburgh School of Medicine/UPMC, Pittsburgh, PA, USA. ¹³Mayo Clinic, Rochester, MN, USA. ¹⁴Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA. ¹⁵Department of Pathology, Duke University Hospital, Durham, NC, USA. ¹⁶Computational Biology Department, School of Computer Science, Carnegie Mellon University, Pittsburgh, PA, USA. ¹⁷Division of Aging Biology, National Institute on Aging (NIA), Bethesda, MD, USA. ¹⁸UConn Health Center, Farmington, CT, USA. ¹⁹Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA. ²⁰Department of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, MI, USA. ²¹School of Computer Science, Carnegie Mellon University, Pittsburgh, PA, USA. ²²Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH, USA. ²³Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, USA. ²⁴Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, USA. ²⁵University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. ²⁶Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI, USA. ²⁷Department of Environmental Medicine, University of Rochester Medical Center, Rochester, NY, USA. ²⁸Department of Biochemistry, Molecular Biology and Biophysics, and Institute on the Biology of Aging and Metabolism, University of Minnesota, Minneapolis, MN, USA. ²⁹The Jackson Laboratory, Farmington, CT, USA. ³⁰Office of Strategic Coordination, Division of Program Coordination, Planning, and Strategic Initiatives Office of the Director National Institutes of Health (NIH), Bethesda, MD, USA. ³¹Center for Healthy Aging, Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark. ³²Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA. ³³Department of Medicine, and Institute for Health Informatics, University of Minnesota, Minneapolis, MN, USA. ³⁴Department of Genetics and the Department of Cell Biology, Yale School of Medicine, Yale University, New Haven, CT, USA. ³⁵Department of Nutritional Sciences & Toxicology, University of Berkeley, Berkeley, CA, USA. ³⁶Department of Internal Medicine, Section on Gerontology & Geriatrics, Wake Forest School of Medicine, Winston-Salem, NC, USA. ³⁷Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. ³⁸New York Genome Center, New York, NY, USA. ³⁹Prescient Design, a Genentech accelerator, New York, NY, USA. ⁴⁰Department of Biology, New York University, New York, NY, USA. ⁴¹Department of Genetics and Development, Columbia University Irving Medical Center, Vagelos College of Physicians & Surgeons, New York, NY, USA. ⁴²Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, NY, USA. ⁴³Department of Neurology, Columbia University Irving Medical Center, Vagelos College of Physicians & Surgeons, New York, NY, USA. ⁴⁴Department of Pathology & Cell Biology, Columbia University Irving Medical Center, Vagelos College of Physicians & Surgeons, New York, NY, USA. ⁴⁵Academic Department of Neuropathology, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK. ⁴⁶Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, NC, USA. ⁴⁷Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA, USA. ⁴⁸Department of Bioengineering, Northeastern University, Boston, MA, USA. ⁴⁹Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN, USA. ⁵⁰Division of Diabetes, Endocrinology and Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USA. ⁵¹Division of Neuroscience, National Institute on Aging (NIA), NIH, Bethesda, MD, USA. ⁵²Cancer Immunology, Hematology, and Etiology Branch, Division of Cancer Biology, National Cancer Institute (NCI), NIH, Bethesda, MD, USA. ⁵³Division of Cancer Biology, National Cancer Institute (NCI), NIH, Bethesda, MD, USA. ⁵⁴Division of Allergy, Immunology & Transplantation, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, USA. ⁵⁵Office of Strategic Coordination, Division of Program Coordination, Planning, and Strategic Initiatives National Institutes of Health (NIH), Bethesda, MD, USA. ⁵⁶Joslin Diabetes Center, Boston, MA, USA. ⁵⁷Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. ⁵⁸Department of Pathology, University of Michigan, Ann Arbor, MI, USA. ⁵⁹Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA. ⁶⁰Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA. ⁶¹Department of Medicine, and Institute for Health Informatics, University of Minnesota, Minneapolis, MN, USA. ⁶²Department of Integrative Biology and Physiology, and Institute on the Biology of Aging and Metabolism, University of Minnesota, Minneapolis, MN, USA. ⁶³Department of Genetics, Cell Biology, and Development, and Institute on the Biology of Aging and Metabolism, University of Minnesota, Minneapolis, MN, USA. ⁶⁴Department of Surgery, University of Minnesota, Minneapolis, MN, USA. ⁶⁵Department of Pharmacology and Chemical Biology and UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. ⁶⁶Center for Pulmonary Vascular Biology and Medicine, Pittsburgh Heart, Lung, Blood, and Vascular Medicine Institute, Division of Cardiology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. ⁶⁷Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY, USA. ⁶⁸Department of Clinical and Translational Research, University of Rochester Medical Center, Rochester, NY, USA. ⁶⁹Departments of Biology and Medicine, University of Rochester, Rochester, NY, USA. ⁷⁰Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. ⁷¹Comprehensive Transplant Center, The Ohio State University Wexner Medical Center, Columbus, OH, USA. ⁷²Department of Cell Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. ⁷³Department of Biochemistry and Institute for Protein Design, University of Washington, Seattle, WA, USA. ⁷⁴Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA. ⁷⁵Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA. ⁷⁶Department of Pathology and Immunology, Washington University in Saint Louis School of Medicine, St. Louis, MO, USA. ⁷⁷Department of Surgery, Washington University in Saint Louis School of Medicine, St. Louis, MO, USA. ⁷⁸Department of Neuroscience, Washington University in Saint Louis School of Medicine, St. Louis, MO, USA. ⁷⁹Department of Cell Biology and Physiology, Washington University in Saint Louis School of Medicine, St. Louis, MO, USA. ⁸⁰Department of Genetics and the McDonnell Genome Institute, Washington University in Saint Louis School of Medicine, St. Louis, MO, USA. ⁸¹Department of Developmental Biology, Washington University in St. Louis, St. Louis, MO, USA. ⁸²Department of Computer Science and Engineering, Washington University in St. Louis, St. Louis, MO, USA. ⁸³Department of Medicine, Division of Gastroenterology, Washington University in Saint Louis School of Medicine, St. Louis, MO, USA. ⁸⁴Department of Medicine, Division of Hematology, Washington University in Saint Louis School of Medicine, St. Louis, MO, USA. ⁸⁵Department of Medicine, Division of Bone and Mineral Diseases, Washington University in Saint Louis School of Medicine, St. Louis, MO, USA. ⁸⁶Department of Medicine (Rheumatology), Yale School of Medicine, Yale University, New Haven, CT, USA. ⁸⁷Department of Pathology, Yale School of Medicine, Yale University, New Haven, CT, USA. ⁸⁸Department of Medicine (Hematology), Yale School of Medicine, Yale University, New Haven, CT, USA. ⁸⁹Department of Medicine, Yale School of Medicine, Yale University, New Haven, CT, USA.  e-mail: patty.lee203@gmail.com